Tatva Chintan Pharma Chem Ltd released the Q4 FY26 earnings call transcript after announcing results. Q4 revenue was ₹1,341 million with EBITDA of ₹281 million, reflecting strong YoY growth across several segments and a favorable product mix, supported by operating leverage.